JATT JATT Acquisition Corp

JATT Acquisition Corp

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

JATT Acquisition Corp intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses primarily operating in the life sciences sector. The company was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

IPO Year: 2021

Exchange: NYSE

Website: jattacquisition.com

Recent Analyst Ratings for JATT Acquisition Corp

Date	Price Target	Rating	Analyst

See more ratings

JATT Acquisition Corp Press Releases

Fastest customizable press release news feed in the world

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp
Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq under ticker "ZURA" commencing March 21, 2023 Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE:JATT) ("JATT"), on March 20, 2023. The business combination was
3/21/23 6:13:00 AM ET
$JATT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited
JATT Acquisition Corp (NYSE:JATT) ("JATT"), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited ("Zura"), a clinical-stage biotechnology company. At the extraordinary general meeting of JATT's shareholders, a total of 4,907,863 ordinary shares, or 95.5% of JATT's issued and outstanding ordinary shares as of February 16, 2023, the record date of the extraordinary general meeting, were present either in person or represented by proxy. Holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor the business combination. At the closing of the bu
3/16/23 4:17:00 PM ET
$JATT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited
JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock Exchange ("NYSE") to the Nasdaq Stock Market LLC ("Nasdaq") in connection with, and upon the closing of, the previously announced business combination (the "Business Combination") with Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"). The Company expects that listing and trading of its listed securities on the NYSE will end at market close on March 20, 2023. The Class A ordinary
3/13/23 9:28:00 AM ET
$JATT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JATT Acquisition Corp's Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC
Record date of Feb 26th 2023 established as well as; Extraordinary general meeting of shareholders to approve the Business Combination set for March 16th 2023 JATT Acquisition Corp (NYSE: "JATT"), the publicly traded special purpose acquisition company ("SPAC"), has today announced that the U.S. Securities and Exchange Commission ("SEC") has declared its registration statement on Form S-4 pertaining to the proposed business combination with Zura Bio Limited ("Zura," "Zura Bio," or "the Company") as effective. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005455/en/ Zura is a UK based multi-asset clinical-stage biotech
3/2/23 7:02:00 AM ET
$JATT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company
Company advancing ZB-168, an anti-IL7Rα monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma enterprise value of $215 million Total gross proceeds of up to $189 million of which up to $139 million is from the cash held in trust (assuming no redemptions) and $50 million from the committed forward purchase agreement and PIPE investments The transaction is expected to be completed in the fourth quarter of 2022 Zura Bio Limited ("Zura Bio"), a clinical-stage biotechnology company focused on developing novel medicines for immune disorders, and JATT Acquisition Corp. ("JATT") (NYSE:JATT, JATT
6/17/22 7:00:00 AM ET
$JATT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

JATT Acquisition Corp

Recent Analyst Ratings for JATT Acquisition Corp

JATT Acquisition Corp

Recent Analyst Ratings for JATT Acquisition Corp

JATT Acquisition Corp Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G filed by JATT Acquisition Corp

SEC Form SC 13D/A filed by JATT Acquisition Corp (Amendment)

SEC Form SC 13G filed by JATT Acquisition Corp

JATT Acquisition Corp Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Lisicki Robert

SEC Form 4 filed by Ploos Van Amstel Arnout

SEC Form 4 filed by Thiara Parvinder

SEC Form 4 filed by Nistala Kiran

SEC Form 3 filed by new insider Lisicki Robert

Thiara Parvinder sold $8,000,000 worth of Class A Ordinary Shares (2,000,000 units at $4.00) (SEC Form 4)

SEC Form 4 filed by Sidhu Someit

SEC Form 3 filed by new insider Nistala Kiran

New insider Ploos Van Amstel Arnout claimed ownership of 20,000 units of Class A ordinary shares (SEC Form 3)

New insider Thiara Parvinder claimed ownership of 6,801,633 units of Class A Ordinary Shares (SEC Form 3)

JATT Acquisition Corp Press Releases

Fastest customizable press release news feed in the world

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited

JATT Acquisition Corp's Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC

JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company

JATT Acquisition Corp SEC Filings

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by JATT Acquisition Corp

JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 424B7 filed by JATT Acquisition Corp